Company intelligence / Profile preview

Sferogen

Ajdovščina or Ljubljana, Sloveniasferogen.com ↗

Ownership: Private
Development stage: Other

Overview

Sferogen has demonstrated strong preclinical immunogenicity with its nanoSFERIC-based vaccine candidates. Its eVLP COVID vaccine showed immune responses in mice on par with approved vaccines. The company is advancing a Nipah virus vaccine for pandemic preparedness and has developed scalable clinical-grade manufacturing processes.

Therapeutic areas: ImmunologyOncologyInfectious DiseasesOther
Modalities: Recombinant proteinNanoparticleEnveloped virus-like particle (eVLP)Protein nanoparticleVaccine (as a product class)
Industry: Biotech

Drug pipeline

6 assets

nanoSFERIC cancer vaccine

Preclinical

5 more assets in the full pipeline.

Partnerships

Not specified; open to partnerships

Beyond the preview

Go deeper on Sferogen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sferogen.